Clinical Report: Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Overview

The first-in-human phase 1 trial of SDC-1801, a TYK2/JAK1 inhibitor, demonstrated good tolerability and biomarker changes indicative of pathway inhibition. The study involved 95 healthy participants and highlighted pharmacokinetic properties and safety profiles.

Background

The TYK2/JAK1 signaling pathway is implicated in various inflammatory and autoimmune diseases. Current treatments for conditions like inflammatory bowel disease (IBD) often leave patients unresponsive.

Data Highlights

Key Findings

• SDC-1801 was well tolerated with no serious adverse events reported.
• Headache was the most common treatment-emergent adverse event.
• Pharmacokinetic analyses indicated a half-life of 15 to 27 hours.
• Food intake modestly increased drug exposure, suggesting improved absorption.
• Evidence of pharmacologic activity included reductions in IP-10 and high-sensitivity C-reactive protein.

Clinical Implications

The safety profile and biomarker effects observed in this study were reported, indicating the need for further evaluation of SDC-1801.

Conclusion

The findings from the phase 1 trial of SDC-1801 indicate its safety and pharmacokinetic properties.

Related Resources & Content

1. Brearley C, et al., British Journal of Clinical Pharmacology, 2023 -- First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801
2. Journal of Crohn's and Colitis — Hit the road JAK: is there still hope left for TYK2 inhibition in IBD?
3. Frontiers in Immunology — JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases
4. Journal of Crohn's and Colitis — Discordant Effects of Janus Kinase Inhibition Ex Vivo on Inflammatory Responses in Colonic Compared to Ileal Mucosa
5. Frontiers in Immunology — Cardiovascular safety and early myocardial deformation signal after upadacitinib initiation in immune-mediated inflammatory disorders
6. Living guideline for pharmacological management of moderate-to-severe ulcerative colitis
7. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update
8. ACG Clinical Guideline Update: Ulcerative Colitis in Adults - PubMed
9. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update - PMC
10. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions | FDA
11. SOTYKTU (deucravacitinib) Highlights of Prescribing Information
12. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials - Armstrong - 2025 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
13. POS0496 DEUCRAVACITINIB IN MODERATE TO SEVERE PLAQUE PSORIASIS: 5-YEAR, LONG-TERM SAFETY AND EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1, PSO-2, AND LTE TRIALS - ScienceDirect
14. Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial - PMC
15. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial - PMC
16. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis - PubMed
17. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 AGA Evidence Synthesis - PMC
18. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis - ScienceDirect
19. Effectiveness and Safety of Janus Kinase Inhibitors in Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis - Clinical Gastroenterology and Hepatology
20. First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801 - Brearley - British Journal of Clinical Pharmacology - Wiley Online Library